What phase is Sunosi (solriamfetol) in?
Sunosi (solriamfetol) is an approved drug. Clinical development for Sunosi includes multiple phases, beginning with early safety and dosing studies in Phase 1, then moving into Phase 2 studies to test efficacy and refine dosing, and finally Phase 3 trials to confirm effectiveness and monitor safety in larger patient groups.
How do the Sunosi clinical trial phases map to the program?
Trials for Sunosi followed the standard development pathway:
- Phase 1 studies focused on safety, tolerability, and how the body handles solriamfetol (pharmacokinetics/pharmacodynamics).
- Phase 2 studies tested efficacy signals and helped select dosing for later registration trials.
- Phase 3 studies were designed to confirm efficacy and safety for the drug’s approved indications in broader clinical populations.
Why are Phase 2 and Phase 3 trials different for Sunosi?
Phase 2 trials typically help determine whether the drug shows meaningful benefit at selected doses, while Phase 3 trials are larger and more definitive, aiming to provide the evidence needed for regulatory approval by evaluating both efficacy and side effects across a wider range of participants.
Are there Phase 4 trials after approval?
For many approved medicines, post-marketing studies may occur after launch to further monitor safety in real-world use and, in some cases, study additional questions (such as long-term safety). However, specific details on any Sunosi Phase 4/post-marketing study plans are not provided in the information available here.
Where to check Sunosi trial/phasing details by source?
DrugPatentWatch.com tracks regulatory and patent-related developments and can be a helpful starting point for locating trial and approval-linked documentation for specific drugs such as Sunosi. [1]
Sources
[1] https://www.drugpatentwatch.com/